The KLOW Stack: KPV, GHK-Cu, BPC-157, and TB-500 in Anti-Inflammatory and Tissue Repair Research
The KLOW Stack combines KPV, GHK-Cu, BPC-157, and TB-500—peptides studied for anti-inflammatory signaling, skin repair, wound healing, and connective tissue regeneration.
The "KLOW Stack" is a community-coined combination of four peptides: KPV, GHK-Cu (copper peptide), BPC-157, and TB-500 (Thymosin Beta-4 fragment). Each compound has been individually studied for anti-inflammatory or tissue repair properties. Taken together, they represent a mechanistically layered approach to managing inflammation and supporting connective tissue, skin, and mucosal health.
The KLOW Stack is an extension of the Glow Stack (GHK-Cu + BPC-157 + TB-500), with KPV added for its more specific anti-inflammatory and gut mucosal effects.
The Distinguishing Component: KPV
KPV (Lys-Pro-Val) is a tripeptide derived from the C-terminal sequence of alpha-melanocyte stimulating hormone (α-MSH). While α-MSH is a 13-amino acid peptide with broad neuroendocrine roles, the KPV fragment has been studied independently for concentrated anti-inflammatory activity — particularly in mucosal and intestinal tissues.
Mechanism
KPV exerts anti-inflammatory effects through melanocortin receptor (MC1R) signaling and through direct inhibition of NF-κB — a key transcription factor driving pro-inflammatory cytokine production. Unlike the full α-MSH peptide, KPV is small enough (tripeptide) to be taken up by intestinal epithelial cells via the PepT1 transporter, which has made it of particular interest in gut inflammation research.
The landmark study by Dalmasso et al. demonstrated that PepT1-mediated KPV uptake in intestinal epithelial cells produced significant reductions in inflammatory markers in both cell culture and murine models of colitis []. KPV reduced IL-8, TNF-α, and NF-κB activation in colonic tissue, with effects measurable at low concentrations.
This mechanistic profile makes KPV the primarily systemic anti-inflammatory component of the stack — addressing upstream inflammatory signaling in a way that the other three compounds do not target as directly.
GHK-Cu: Extracellular Matrix and Skin Regeneration
GHK-Cu is a naturally occurring tripeptide (Gly-His-Lys) that chelates copper and is found endogenously in human plasma, though its concentration declines with age. Research has focused on its role in stimulating collagen synthesis, remodeling the extracellular matrix, and modulating inflammation through NF-κB inhibition — a pathway it shares with KPV, suggesting potential complementarity in the inflammatory signaling domain.
Gene expression analysis suggests GHK-Cu influences thousands of human genes related to tissue repair and regeneration []. While the clinical significance of this broad gene regulation profile remains to be established in controlled trials, the mechanistic groundwork for GHK-Cu in skin and connective tissue repair is among the better-characterized in this compound class.
See Copper Peptides: GHK-Cu Research Overview for the full evidence review.
BPC-157: Vascular and Connective Tissue Repair
BPC-157 is a synthetic 15-amino acid pentadecapeptide derived from a protein in human gastric juice. Its research profile spans gastrointestinal, musculoskeletal, and systemic tissue repair, with the strongest evidence concentrated in rodent models of gut injury and wound healing.
In the context of the KLOW Stack, BPC-157 contributes angiogenic support through VEGF upregulation, nitric oxide pathway modulation relevant to vascular health, and connective tissue repair mechanisms studied in tendon, muscle, and skin models [].
The combination of BPC-157 with GHK-Cu is particularly common in research discussions because they address sequential steps in tissue repair: BPC-157 supports the vascular and inflammatory environment, while GHK-Cu drives extracellular matrix reconstruction.
See BPC-157: Research and Mechanisms of Action for detail.
TB-500: Cell Migration and Re-epithelialization
TB-500 corresponds to the active fragment of Thymosin Beta-4, a ubiquitous intracellular peptide involved in actin regulation and cytoskeletal dynamics. Its mechanism in wound healing involves promoting keratinocyte and endothelial cell migration across wound surfaces — the re-epithelialization step that is essential for wound closure and skin repair.
Research on Thymosin Beta-4 has progressed further toward clinical applications than most peptides in this space, with studies in corneal wound healing and cardiac injury models that have included human data []. This gives TB-500 a somewhat more developed preclinical-to-clinical translation record than BPC-157 or KPV.
In the KLOW Stack, TB-500 addresses the cellular migration component of repair — the phase following the inflammatory resolution that KPV and GHK-Cu support.
See TB-500 and Thymosin Beta-4: Research Overview.
Mechanistic Framework for the Stack
The four compounds span the tissue repair cascade from early inflammation through final remodeling:
| Phase | Component | Studied Mechanism |
|---|---|---|
| Inflammatory signaling | KPV | NF-κB inhibition, MC1R signaling, mucosal anti-inflammatory |
| ECM remodeling | GHK-Cu | Collagen synthesis, MMP/TIMP regulation, anti-inflammatory |
| Vascular / connective repair | BPC-157 | Angiogenesis, NO pathway, FAK signaling |
| Cell migration / re-epithelialization | TB-500 | Actin regulation, keratinocyte and endothelial migration |
This layered model is the mechanistic rationale most commonly cited in research community discussions. Whether the compounds produce genuinely additive or synergistic effects in living tissue is not established — no controlled combination study has been published.
Comparison to the Glow Stack
The primary distinction between KLOW and the Glow Stack is the inclusion of KPV:
- Glow Stack (GHK-Cu + BPC-157 + TB-500): Focused on skin regeneration and soft tissue repair
- KLOW Stack (KPV + GHK-Cu + BPC-157 + TB-500): Extends the profile to include upstream anti-inflammatory and gut mucosal signaling
Research community discussions suggest the KLOW stack is often considered when systemic or gut inflammation context is present alongside tissue repair goals — given KPV's documented activity in intestinal epithelial cells.
Evidence Limitations
No human clinical data for the stack or its components in combination. All mechanistic evidence for KLOW as a combined protocol is derived from individual compound studies, primarily in animal models. The "stack" concept is a community-derived framework, not a clinically tested protocol.
KPV data is concentrated in gut models. The strongest KPV evidence is in intestinal inflammation. Systemic anti-inflammatory effects beyond the gut are less well-characterized in the published literature.
Regulatory status. None of the four compounds are approved pharmaceutical products for the applications discussed here. They are not available as licensed drugs and are not regulated as dietary supplements. Their use outside controlled research settings is not sanctioned by regulatory agencies.
For guidance on evaluating evidence quality in this space, see Evaluating Peptide Research Claims and Understanding Clinical Trials for Peptide Drugs.
References
- 1.Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. “PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.” Gastroenterology. 2008;134(1):166-178. doi:10.1053/j.gastro.2007.10.026 [PubMed]
- 2.Pickart L, Margolina A. “Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.” International Journal of Molecular Sciences. 2018;19(7):1987. doi:10.3390/ijms19071987 [PubMed]
- 3.Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Stambolija V, George N, Pavlov KH, Kalogjera L. “Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications.” Current Neuropharmacology. 2016;14(8):857-865 [PubMed]
- 4.Goldstein AL, Hannappel E, Sosne G, Kleinman HK. “Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications.” Expert Opinion on Biological Therapy. 2012;12(1):37-51. doi:10.1517/14712598.2012.634793 [PubMed]